Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans

被引:138
作者
Keaveny, Tony M. [1 ,2 ]
Hoffmann, Paul F. [2 ]
Singh, Mandeep [2 ]
Palermo, Lisa [3 ]
Bilezikian, John P. [4 ]
Greenspan, Susan L. [5 ]
Black, Dennis M. [3 ]
机构
[1] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA
[2] ON Diagnost, Berkeley, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[5] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
关键词
bone strength; osteoporosis; drug therapy; clinical trials; biomechanics;
D O I
10.1359/JBMR.080805
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The "PTH and Alendronate" or "PaTH" study compared the effects of PTH(1-84) and/or alendronate (ALN) in 238 postmenopausal, osteoporotic women. We performed finite element analysis on the QCT scans of 162 of these subjects to provide insight into femoral strength changes associated with these treatments and the relative roles of changes in the cortical and trabecular compartments on such strength changes. Patients were assigned to either PTH, ALN, or their combination (CMB) in year 1 and were switched to either ALN or placebo (PLB) treatment in year 2: PTH-PLB, PTH-ALN, CMB-ALN, and ALN-ALN (year 1-year 2) treatments. Femoral strength was simulated for a sideways fall using nonlinear finite element analysis of the quantitative CT exams. At year 1, the strength change from baseline was statistically significant for PTH (mean, 2.08%) and ALN (3.60%), and at year 2, significant changes were seen for the PTH-ALN (7.74%), CMB-ALN (4.18%), and ALN-ALN (4.83%) treatment groups but not for PTH-PLB (1.17%). Strength increases were primarily caused by changes in the trabecular density regardless of treatment group, but changes in cortical density and mass also played a significant role, the degree of which depended on treatment. For PTH treatment at year 1 and for ALN-ALN treatment at year 2, there were significant negative and positive strength effects, respectively, associated with a change in external bone geometry. Average changes in strength per treatment group were somewhat consistent with average changes in total hip areal BMD as measured by DXA, except for the PTH group at year 1. The relation between change in femoral strength and change in areal BMD was weak (r(2) = 0.14, pooled, year 2). We conclude that femoral strength changes with these various treatments were dominated by trabecular changes, and although changes in the cortical bone and overall bone geometry did contribute to femoral strength changes, the extent of these latter effects depended on the type of treatment.
引用
收藏
页码:1974 / 1982
页数:9
相关论文
共 57 条
[1]
Raloxifene enhances vertebral mechanical properties independent of bone density [J].
Allen, Matthew R. ;
Iwata, Ken ;
Sato, Masahiko ;
Burr, David B. .
BONE, 2006, 39 (05) :1130-1135
[2]
Comparison of the elastic and yield properties of human femoral trabecular and cortical bone tissue [J].
Bayraktar, HH ;
Morgan, EF ;
Niebur, GL ;
Morris, GE ;
Wong, EK ;
Keaveny, TM .
JOURNAL OF BIOMECHANICS, 2004, 37 (01) :27-35
[3]
PREDICTING FEMORAL-NECK STRENGTH FROM BONE-MINERAL DATA - A STRUCTURAL APPROACH [J].
BECK, TJ ;
RUFF, CB ;
WARDEN, KE ;
SCOTT, WW ;
RAO, GU .
INVESTIGATIVE RADIOLOGY, 1990, 25 (01) :6-18
[4]
Prediction of strength and strain of the proximal femur by a CT-based finite element method [J].
Bessho, Masahiko ;
Ohnishi, Isao ;
Matsuyama, Juntaro ;
Matsumoto, Takuya ;
Imai, Kazuhiro ;
Nakamura, Kozo .
JOURNAL OF BIOMECHANICS, 2007, 40 (08) :1745-1753
[5]
Side-artifact errors in yield strength and elastic modulus for human trabecular bone and their dependence on bone volume fraction and anatomic site [J].
BeVill, Grant ;
Easley, Sarah K. ;
Keaveny, Tony M. .
JOURNAL OF BIOMECHANICS, 2007, 40 (15) :3381-3388
[6]
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[7]
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].
Black, DM ;
Bilezikian, JP ;
Ensrud, KE ;
Greenspan, SL ;
Palermo, L ;
Hue, T ;
Lang, TF ;
McGowan, JA ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565
[8]
DXA in vivo BMD methodology:: An erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling [J].
Bolotin, H. H. .
BONE, 2007, 41 (01) :138-154
[9]
Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography [J].
Borah, B ;
Dufresne, TE ;
Chmielewski, PA ;
Gross, GJ ;
Prenger, MC ;
Phipps, RJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (07) :1139-1147
[10]
Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone [J].
Bousson, V ;
Bras, A ;
Roqueplan, F ;
Kang, Y ;
Mitton, D ;
Kolta, S ;
Bergot, C ;
Skalli, W ;
Vicaut, E ;
Kalender, W ;
Engelke, K ;
Laredo, JD .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (06) :855-864